April 27, 2010
Asahi Kasei Pharma Corp.

Preliminary Results of Phase III clinical study of AT-877 for acute cerebral infarction
Asahi Kasei Pharma has unblinded the data from a Phase III clinical study of AT-877 (fasudil hydrochloride hydrate) for acute cerebral infarction. Preliminary analysis indicates that the study's primary efficacy endpoint was not met.

Asahi Kasei Pharma will perform a detailed analysis of the results of this study and make a final decision regarding the possibility for further clinical development of fasudil hydrochloride hydrate for acute cerebral infarction.
Note: Fasudil hydrochloride hydrate is sold as Eril™ injection 30 mg for cerebral vasospasm and associated cerebral ischemic symptoms following surgery for subarachnoid hemorrhage (SAH).


Adobe Readeris required to view these PDF files.

page top